2021-2024年某肿瘤专科医院大分子单克隆抗体类抗肿瘤药物应用分析OA

OBJECTIVE:To probe into the clinical application of macromolecular monoclonal antibody anti-tumor drugs in the hospital,and to provide reference for promoting standardized management and clinical application of these drugs.METHODS:Through the retrospective method,the consumption and clinical application of macromolecular monoclonal antibody anti-tumor drugs in the hospital from 2021 to 2024 were collected.The changes in trends of indicators such as the number of drug varieties,consumption sum and ranking,defined daily dose system(DDDs)and ranking,defined daily cost(DDC),and ranking ratio(B/A,consumption sum ranking/DDDs ranking)were statistically analyzed on an annual basis.RESULTS:From 2021 to 2024,the number of varieties of macromolecular monoclonal antibody anti-tumor drugs in the hospital ranged from 14 to 22,increasing year by year;the annual consumption sum increased from 15.292 5 million RMB in 2021 to 42.962 6 million RMB in 2024,with a significant growth in the period from 2023 to 2024.The top three drugs ranked by consumption sum were bevacizumab,trastuzumab,and camrelizumab.Total DDDs of macromolecular monoclonal antibody anti-tumor drugs showed a year-on-year upward trend,with camrelizumab ranking first in DDDs for three consecutive years,while trastuzumab and tislelizumab remained in the top five for four years.Total DDC of macromolecular monoclonal antibody anti-tumor drugs initially increased and then declined,with drugs such as bevacizumab,daratumumab,camrelizumab,and tislelizumab showing decreasing DDC trends.The number of drugs with B/A ratios between 0.8 and 1.2 ranged from 7 to 10,primarily including trastuzumab,pertuzumab,rituximab,and cetuximab.CONCLUSIONS:From 2021 to 2024,the consumption sum,variety,and DDDs of macromolecular monoclonal antibody anti-tumor drugs in the hospital show a rapid growth trend.The economic and social benefits of most drugs are well synchronized.The medication situation conform to the clinical treatment needs of cancer patients in the hospital and the policy guidance trend of the national medical insurance.